Premium
FDA issues final guidance on abuse‐deterrent opioids
Publication year - 2015
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30042
Subject(s) - food and drug administration , opioid abuse , substance abuse , medicine , deterrence (psychology) , business , opioid , medical emergency , psychiatry , criminology , psychology , receptor
On April 1, the Food and Drug Administration issued final guidance on the development of opioids with abuse‐deterrent properties. The FDA is encouraging manufacturers to develop drugs that work when taken as prescribed but deter misuse or abuse, including making it difficult to snort or inject the drugs. While deterrence is not “abuse‐proof,” the FDA said, it is a step toward balancing access to needed medications with the reduction of abuse.